[
  {
    "ts": null,
    "headline": "Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?",
    "summary": "Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=a1c4550629d24967f66550f489c66ce8684f4c9e659cbe5c54e4a1b6bea2b6d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769692980,
      "headline": "Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?",
      "id": 138297220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=a1c4550629d24967f66550f489c66ce8684f4c9e659cbe5c54e4a1b6bea2b6d2"
    }
  },
  {
    "ts": null,
    "headline": "Gilead’s Trodelvy Win In TNBC Highlights Evolving Oncology Growth Story",
    "summary": "Gilead Sciences reported positive Phase 3 results for Trodelvy in combination with Keytruda in first-line PD-L1+ metastatic triple-negative breast cancer. The data were published in The New England Journal of Medicine, with new regulatory submissions underway to the FDA and EMA. The update centers on Trodelvy's role in Gilead's oncology pipeline and the potential for expanded use in breast cancer treatment. Gilead Sciences, listed as NasdaqGS:GILD, is drawing attention as it advances its...",
    "url": "https://finnhub.io/api/news?id=5ea709924b2718e3672f03f14d6d814178c4fd1bc07702eaa7e753a651ee31f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769656694,
      "headline": "Gilead’s Trodelvy Win In TNBC Highlights Evolving Oncology Growth Story",
      "id": 138291574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences reported positive Phase 3 results for Trodelvy in combination with Keytruda in first-line PD-L1+ metastatic triple-negative breast cancer. The data were published in The New England Journal of Medicine, with new regulatory submissions underway to the FDA and EMA. The update centers on Trodelvy's role in Gilead's oncology pipeline and the potential for expanded use in breast cancer treatment. Gilead Sciences, listed as NasdaqGS:GILD, is drawing attention as it advances its...",
      "url": "https://finnhub.io/api/news?id=5ea709924b2718e3672f03f14d6d814178c4fd1bc07702eaa7e753a651ee31f7"
    }
  }
]